



Subscription period:
6-20 July 2022

Invitation to subscribe for units

Prostatype Genomics AB



IMPORTANT INFORMATION

The following summary is not a complete offer but should be seen as an introduction to Prostatype Genomics AB ("Prostatype Genomics" or "the Company") and the prospectus that describes the offer in its entirety. Thus, this document does not necessarily contain all the information that may be needed for an investment decision. All investors are asked to look at the prospectus available on the Company's website (www.prostatypegenomics.com) to find out about the potential risks associated with the decision to invest in the securities, before making a decision to invest. Prostatype Genomics AB, corp. id. no. 556726-0285.

Prostatype®

– a genetic test for risk assessment of prostate cancer

Prostate cancer is globally the second most common form of cancer among men. Every year, about 1.3 million men are diagnosed with prostate cancer.¹ In Sweden alone, it is currently estimated that about 100,000 men live with prostate cancer and every year about 10,000 men get newly diagnosed prostate cancer.² Today's methods for predicting prostate cancer are highly dependent on human interpretation and subjectivity, which can lead to overtreatment or undertreatment.

Prostatype Genomics is active in the development of medical genetic tests that are used for identification, analysis, and further follow-up of prostate cancer. Today, Prostatype Genomics provides the CE-marked, patented and market-launched product Prostatype®, which is a test for the prognosis of prostate cancer. Prostatype® has been developed to optimize the treatment strategy for each patient and reduce the risk of overtreatment or undertreatment.

Prostatype® uses the patient's existing biopsy

Prostatype® is intended to be used as a complement to the current clinical diagnostic and prognostic methods routinely used by healthcare providers. The Company does this by using the patient's existing biopsy, which means that the patient does not need to undergo further tests to be able to predict how aggressive the prostate cancer is. The test can be performed in most laboratories and at Prostatype Genomics ISO13485-certified laboratory in Stockholm. The test analyzes the expression of the genes in cancer cells from the prostate tissue taken at biopsy, which in combination with an advanced algorithm and data analysis provides decision support for optimal treatment of individual patients when prostate cancer has been confirmed.

Intensive commercialization phase with partial focus on the US

Prostatype® is currently in the commercialization phase and the Company has initiated sales in Sweden, Germany, Italy, Spain, Portugal, the United Kingdom and China. Market processing takes place both with own resources as well as distributors and partners, optimized according to the market structure.

In order to primarily intensify the commercialization of Prostatype® in selected European markets and in the US and Asia, Prostatype Genomics is now carrying out a rights issue of units that can initially provide the Company with a maximum of approximately SEK 22.5 million before issue costs and at a later stage a maximum of approximately 22.5 MSEK.

The offer in brief

Subscription period: 6–20 July 2022.

Subscription price: SEK 55.10 per unit, corresponding to SEK 2.90 per share. The warrants are issued free-of-charge. Brokerage is not payable.

Issue volume: The offer comprises a maximum of 408,205 units, which corresponds to 7,755,895 shares and 7,755,895 warrants of series TO 2. The Company can initially be provided proceeds of approximately SEK 22.5 million before issue costs. Through the exercise of warrants of series TO 2, the Company can be provided an additional maximum of approximately SEK 22.5 million during Q1 2023.

Pre-emptive right for subscription: Those who on the record date of June 30, 2022, were registered as shareholders in the Company have a preferential right to subscribe for units in the rights issue in relation to previous holdings, whereby one (1) existing share gives one (1) unit right. Thirty-seven (37) unit rights entitle to subscribe for one (1) unit. Each unit consists of nineteen (19) newly issued shares and nineteen (19) warrants of series TO 2.

Guarantee- and pre-subscription commitments: Approximately SEK 22.5, corresponding to 100 percent of the initial issue volume, is covered by guarantee- and pre-subscription commitments.

Marketplace: Nasdaq First North Growth Market.

Trading in unit rights: Trading in unit rights will take place on Nasdaq First North Growth Market from the 6th of July 2022 until the 15th of July 2022.

Trading in BTU: Trading in BTU (Paid Subscribed Unit) will take place on Nasdaq First North Growth Market from the 6th of July 2022 until the Companies Registration Office has registered the issue. The registration is expected to take place around week 32, 2022.

Dilution: For the existing shareholders who choose not to use their unit rights to subscribe for units, a maximum dilution of approximately 34 percent will be recognized through the initial issue. Upon full exercise of TO 2, the dilution amounts to an additional approximately 25 percent.

Warrants of series TO 2: Holders of warrants of series TO 2 have, during the exercise period from the 9th of March 2023 until the 30th of March 2023, the right to subscribe for a new share in the Company for each warrant, at an exercise price which is the same price per share as the subscription price in the initial part of the rights issue, i.e. SEK 2.90 per share. If all warrants of series TO 2 are exercised, the Company will receive an additional approximately SEK 22.5 million before issue costs.

1. Umeå Biotech Incubator (2022). Phenotype Diagnostics – Novel method for risk assessment and treatment stratification in men with prostate cancer. <https://www.ubi.se/case/novel-method-for-risk-assessment-and-treatment-stratification-in-men-with-prostate-cancer/> [Retrieved 2022]

2. Prostatacancerförbundet (2022). Prostatacancer. <https://prostatacancerforbundet.se/prostatacancer/> [Retrieved 2022]



Great global market potential

There is a clear global need for better prognostic tools in prostate cancer, and according to the Board's assessment, the global annual market potential amounts to approximately SEK 8.5 billion. The Board estimates that the annual addressable market for Prostatype Genomics amounts to approximately SEK 5.5 billion, which corresponds to approximately 65 percent of the total market. Since about 1.3 million men around the world are diagnosed with prostate cancer,³ the Board estimates that approximately 845,000 patients can be added to the Company's addressable market every year.



Objectives

Prostatype Genomics has set several goals for the coming years. The objectives are primarily that the Company intends to enter into partnerships with laboratories and distributors and to establish sales in selected markets around the world. In addition, the Company intends to strengthen its market presence by conducting validation studies in various markets.

Financial objectives

The Company is expected to generate organic sales growth of approximately 250–400 percent per year over the next three financial years as a result of accelerated commercialization and increased market shares. After that, growth is expected to be high for the foreseeable future.

"With Prostatype[®], it is possible to decide which treatment strategy that is optimal for each patient diagnosed with prostate cancer."



Operational objectives

2022

- Sales start in Germany
- Sales start in Italy
- Recruitment of CEO in the US
- Initiate a validation study in the US

2023

- Enter into agreement with a first distributor in the US
- Sales start in the US
- Sales start in Taiwan
- Enter into agreement with an additional two to three distributors in the US

2024

- Sales start in France
- Provide extended reimbursement from the US National Insurance System
- Provide private insurance coverage for Prostatype[®] in the United Kingdom
- Provide private insurance coverage for Prostatype[®] in Spain

Above is a selection of the Company's objectives. Complete objectives are presented in the Company's prospectus, which is available at www.prostatypegenomics.com.

1. Umeå Biotech Incubator (2022). Phenotype Diagnostics – Novel method for risk assessment and treatment stratification in men with prostate cancer. <https://www.ubi.se/case/novel-method-for-risk-assessment-and-treatment-stratification-in-men-with-prostate-cancer/> [Retrieved 2022]

CEO Fredrik Persson has the floor

Being diagnosed with prostate cancer is tough news. What many men do not know, however, is that the majority of all prostate tumours develop slowly and are limited to the prostate gland.


The tumour often grows so slowly that in many cases the patient dies for other reasons before the prostate cancer has become life-threatening. Of course, many patients want to be free of cancer and having surgical removal of the prostate or undergoing radiation therapy can accomplish this. The problem, however, is that a very high proportion of all men who undergo aggressive cancer treatment are forced to suffer serious and lifelong side effects. Studies show that about 50 percent of patients suffer from impotence and about 10-20 percent suffer from incontinence as a result of the radical treatment methods.⁴

With today's methods, it is in many cases difficult to determine with certainty how aggressive the cancer is and thus determine which treatment method is necessary. This is where our product Prostatype[®] can help. Prostatype[®] is a genetic test that has been developed to provide the additional information needed to optimize the treatment strategies for each prostate cancer patient. Prostatype[®] has undergone several studies with impressive results despite high expectations. One of the most recent studies, conducted at Uppsala University, confirmed, for example, that Prostatype[®] helps to determine with greater certainty the next step in the treatment of the patient. The study has attracted a great deal of interest and the results were presented at the American Urology Association in New Orleans, the US, in May 2022.

Today, we are in an intensive commercialization phase with a broad market presence through distributors and our own employees in the United Kingdom, Spain, Germany and Italy, among others. Sales have begun in Sweden, Germany and China, and we are working intensively to enter priority markets in Europe, Asia and the US. We see the US as one of the markets with the greatest potential, this because the awareness of this type of test is significantly greater, and that prognostic tests for prostate cancer are already covered via both private and public insurance systems. This, of course, makes an American establishment very interesting from a commercial perspective. In 2023, we aim to start sales in the US through our newly established subsidiary, Prostatype Genomics Inc.

Patients and urologists in all priority markets have confirmed that Prostatype[®] fills a great need that has been lacking in the market so far. I am convinced that Prostatype[®] has the potential to significantly increase the quality of life for millions of patients with prostate cancer, while at the same time reducing society's total annual health care costs. In order to intensify the commercialization of Prostatype[®] and help more patients to know how aggressive (or non-aggressive) their prostate cancer is, we are now conducting a rights issue. With the added capital, Prostatype Genomics will be well equipped to accelerate the growth journey with increased sales and entry into more markets. You are very welcome to invest in Prostatype Genomics!

Fredrik Persson
CEO, Prostatype Genomics



Fredrik Persson, VD | Prostatype Genomics AB

"Prostatype[®] has the potential to significantly increase the quality of life for millions of patients with prostate cancer, while at the same time reducing society's total annual health care costs."

4. Van Den Bergh, R. C. N. et al. Sexual function with localized prostate cancer: Active surveillance vs radical therapy. *BJU Int.* (2012) doi:10.1111/j.1464-410X.2011.10846.x.; Resnick, M. J. et al. Long-term functional outcomes after treatment for localized prostate cancer. *N. Engl. J. Med.* (2013) doi:10.1056/NEJMoa1209978.; Grabbert, M. et al. Long-term functional outcome analysis in a large cohort of patients after radical prostatectomy. *Neurourol. Urodyn.* 37, 2263-2270 (2018).; Pompe, R. S. et al. Short- and Long-term Functional Outcomes and Quality of Life after Radical Prostatectomy: Patient-reported Outcomes from a Tertiary High-volume Center. *Eur. Urol. Focus* 3, 615-620 (2017).

TERMS AND CONDITIONS FOR THE OFFER

THE OFFER

At a Board meeting on the 23rd of June 2022, the Board decided, with the support from an authorization from the Annual General Meeting, to execute a rights issue of units (shares and free-of-charge warrants) through which the Company's share capital can initially increase with a maximum of SEK 465,353.70 through an issue of a maximum of 408,205 units, each with a quota value of SEK 0.06 per share. The public is also invited to subscribe for units in the rights issue. The total issue volume in the initial issue amounts to SEK 22,492,095.50 at the highest.

PRE-EMPTIVE RIGHT TO SUBSCRIBE

Those who were shareholders in the Company on the record date of the 30th of June 2022 have preferential right to subscribe for units in the rights issue in relation to previous holdings, whereby one (1) existing share gives one (1) unit right. Thirty-seven (37) unit rights entitle the holder to subscribe for one (1) unit. Each unit consists of nineteen (19) newly issued shares and nineteen (19) free warrants of series TO 2. This means that a maximum of 7,755,895 warrants of series TO 2 will be issued in the rights issue.

ISSUE VOLUME

The offer comprises a maximum of 408,205 units (shares and free-of-charge warrants). The total issue volume in the initial issue amounts to a maximum of SEK 22,492,095.50 before transaction related costs.

WARRANTS OF SERIES TO 2

One (1) warrant of series TO 2 entitles to subscription of one (1) new share in the Company and can be exercised from the 9th of Mars 2023 until the 30th of March 2023. Provided that the initial issue is fully subscribed and all attached warrants of series TO 2 are exercised, the share capital will increase with an additional SEK 465,353.70 SEK.

The warrant will be traded from the day that the conversion of BTU into shares and warrants has taken place in Euroclear's system until the 28th of March 2023 and will be traded in Swedish kronor. The warrants have ISIN code SE0018220014.

Complete terms and conditions for warrants of series TO 2 are available on the Company's website (www.prostatypegenomics.com).

SUBSCRIPTION PRICE

The subscription price is SEK 55.10 per unit, which means that the price per share is set to SEK 2.90. No brokerage fee is payable.

RECORD DATE

Record date in Euroclear Sweden AB's ("Euroclear") system for the right to participate in the rights issue was the 30th of June 2022. Last day of trading in the Company's share with the right to participate in the rights issue was on the 28th of June 2022. First day of trading in the Company's share without the right to participate in the rights issue was on the 29th of June 2022.

SUBSCRIPTION PERIOD

Subscription of units with the support of unit rights shall take place during the period from and including the 6th of July 2022 to and including the 20th of July 2022. The Board of Directors of the Company reserves the right to extend the subscription period. A possible extension will be announced by the Company through a press release no later than on the 20th of July 2022.

UNIT RIGHTS

For each existing share held on the record date, one (1) unit right is received. Unit rights entitle the holder to subscribe for new units with preferential rights, whereby thirty-seven (37) unit rights give the right to subscribe for one (1) new unit.

TRADING IN UNIT RIGHTS

Trading in unit rights takes place on the Nasdaq First North Growth Market during the period from the 6th of July 2022 to the 15th of July 2022. Shareholders must contact their bank or other nominee directly with the necessary permits to complete the purchase and sale of unit rights. Unit rights acquired during the above-mentioned trading period give, during the subscription period, the same right to subscribe for units as the unit rights shareholders receive based on their holdings in the Company on the record date.

UNUSED UNIT RIGHTS

Unit rights which have not been sold no later than on the 15th of July 2022 or are used for subscription of units no later than on the 20th of July 2022 will be booked away from all VP accounts without compensation. No special notification is made when cancelling unit rights.

ISSUE REPORT AND NOTIFICATIONS

Direct registered shareholders in Euroclear

Shareholders or representatives of shareholders who were registered with Euroclear on the record date of the 30th of June 2022, will receive a pre-printed issue report with attached payment notice, as well as a leaflet containing a summary of the terms of the rights issue with reference to the full prospectus. Information will be available on Nordic Issuing's website (www.nordic-issuing.se) and on the Company's website (www.prostatypegenomics.com) for download.

Anyone who is included in the list of mortgagees and others specially kept in connection with the share register does not receive any information but is notified separately. VP-slip, which reports the registration of unit rights in shareholders' VP accounts, was not sent out.

SUBSCRIPTION WITH SUPPORT OF UNIT RIGHTS

Subscription with support of unit rights must be made by simultaneous cash payment no later than on the 20th of July 2022. Subscription by payment must be made either with the pre-printed payment notice attached to the issue report, or by payment instructions on the application form for subscription based on unit rights according to the following two alternatives:

1. Issue report – pre-printed payment slip

In the event that all unit rights received on the record date are used for subscription, only the pre-printed payment slip shall be used as a basis for subscription by cash payment. The subscription form for subscription with the support of unit rights shall then not be used.

2. Subscription form with support of unit rights

In the event that a different number of unit rights than those stated in the pre-printed issue report are used for subscription, e.g. by acquiring or selling unit rights, the application form for subscription with the support of unit rights shall be used as a basis for subscription by cash payment. The shareholder must state on the application form the number of unit rights that are exercised, the number of units that he subscribes for and the amount to be paid. Incomplete or incorrectly completed application form may be disregarded. Registration form for subscription with the support of unit rights can be obtained from Nordic Issuing's website www.nordic-issuing.se. Completed application form must be emailed in connection with payment as below and be received by Nordic Issuing no later than on the 20th of July 2022. Registration is binding. Nordic Issuing reserves the right to disregard application slips received by post, as it cannot be guaranteed that they will be received before the last day of the subscription period if they are posted.

Errand: Prostatype Genomics AB

E-mail: info@nordic-issuing.se (inskannad anmälningssedel)

Nominee registered shareholders

Shareholders whose holdings of shares in the Company are nominee-registered with a bank or other nominee do not receive an issue report, however, a leaflet was sent containing a summary of the terms of the rights issue and a reference to a complete prospectus. Subscription and payment must instead be made in accordance with instructions from the respective bank or trustee. Please note that in the event that unit rights are exercised via a bank or trustee, this should be done early in the subscription period because each bank / trustee can set different time limits for the last day for subscription.

SUBSCRIPTION WITHOUT SUPPORT OF UNIT RIGHTS

Application for subscription of units without the support of unit rights must be made on the application form "Subscription without support of unit rights", which can be downloaded from Nordic Issuing's website (www.nordic-issuing.se) and on the Company's website (www.prostatypegenomics.com). Subscription can also be done digitally at www.nordic-issuing.se.

For nominee-registered shareholders, notification of subscription of units without unit rights must be made to the respective nominee and in accordance with instructions from him, or if the holding is registered with several nominees, from each of these. Subscription can also take place through the application form "Subscription without the support of unit rights". In order to be able to invoke subsidiary preferential rights, it is required that the subscription is carried out via the nominee, as otherwise there is no possibility of identifying a particular subscriber who has subscribed for shares both with and without the support of subscription rights.

Please note that those who have a custodian with specific rules for securities transactions, such as an investment savings account (ISK) or endowment insurance account (KF), must check with the bank or manager who maintains the account, if acquisition of securities within the offer is possible. In that case, the notification must be made in agreement with the bank / manager who maintains the account.

Incomplete or incorrectly completed subscription form may be disregarded. It is only permitted to submit one (1) subscription form "Subscription without support of unit rights", in case more than one such application form is submitted, only the last received will be considered, and other such application forms will thus be disregarded. The application form must be received by Nordic Issuing no later than on the 20th of July 2022. Subscription is binding. Nordic Issuing reserves the right to disregard subscription forms received by post, as it cannot be guaranteed that they will be received before the last day of the subscription period if they are posted.

SUBSCRIPTION OVER EUR 15,000

In the event that the subscription amounts to or exceeds EUR 15,000, the money laundering form must be completed and submitted to Nordic Issuing in accordance with the Act (2017: 630) on measures against money laundering and terrorist financing. Please note that Nordic Issuing cannot book securities, even though payment has been received, until the money laundering control is available to Nordic Issuing.

ALLOCATION FOR SUBSCRIPTION WITHOUT PRE-EMPTIVE RIGHT

In the event that not all units are subscribed for with pre-emptive rights in accordance with the above, the Board shall, within the maximum amount of the rights issue, decide on the allocation of units to another who has subscribed for units without pre-emptive rights and decide on distribution between subscribers.

In the first instance, allotment of units subscribed for without the support of unit rights shall take place to such subscribers who have also subscribed for units with the support of unit rights, regardless of whether the subscriber was a shareholder on the record date or not, and in the event that allotment cannot be made in full, allocation shall be made pro rata in relation to the number of unit rights used for subscription of units and, insofar as this cannot be done, by drawing lots.

In the second instance, allotment of units subscribed for without the support of unit rights shall take place to others who have subscribed without the support of unit rights, and in the event that allotment to these cannot be made in full, allotment shall be made pro rata in relation to the number of units one drawn and, in so far as this cannot be done, by drawing lots.

Thirdly, the allocation of units subscribed for without the support of unit rights shall be made to the issue guarantors in proportion to the size of the guaranteed commitments, and to the extent that this cannot be done, by drawing lots.

NOTICE OF ALLOCATION OF UNITS SIGNED WITHOUT PRE-EMPTIVE RIGHTS

Notice of any allocation of units, subscribed without pre-emptive rights, is provided by sending an allocation notice in the form of a settlement note via e-mail. Settlement notes are expected to be sent out as soon as possible after the end of the subscription period and payment must, according to the instructions on the settlement note, no later than four (4) banking days thereafter. Note that there is no possibility to withdraw the amount from the specified VP account or depository. If payment is not made on time, units may be transferred to another. Should the sales price in the event of such a transfer fall below the price in accordance with the Offer, the person who originally received the allotment of these units may be liable for all or part of the difference. No notice is given to the person who has not received allocation.

SHAREHOLDERS RESIDING ABROAD

Shareholders residing outside Sweden (does not refer to shareholders resident in the US, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, South Korea, Russia, Belarus, or other countries where participation requires additional prospectus, registration or other measures than those who follow Swedish law) and who have the right to subscribe for units in the rights issue, can contact Nordic Issuing for information on subscription and payment.

Due to securities law restrictions in the US, Australia, Japan, Canada, New Zealand, South Africa, Hong Kong, Switzerland, Singapore, South Korea, Russia, Belarus, or other countries where participation requires additional prospectuses, registrations or actions other than those resulting from Swedish law, no unit rights will be offered to holders with registered addresses in any of these countries. Accordingly, no offer is made to subscribe for units in the Company to shareholders in these countries.

PAID SUBSCRIBED UNIT (BTU)

Subscription by payment is registered with Euroclear as soon as this can be done, which normally means a few banking days after payment. Thereafter, a directly registered subscriber receives a VP notification with confirmation that paid subscribed units (BTU) have been booked on the subscriber's VP account. Subscribed units are booked as BTU in the VP account until the rights issue has been registered with the Swedish Companies Registration Office.

Shareholders who have their holdings in a depository with a bank or nominee receive information from the respective nominee.

TRADING IN BTU

Trading with BTU takes place on Nasdaq First North Growth Market from and including the 6th of July 2022 until the rights issue is registered with the Swedish Companies Registration Office. Subscribed units are booked as BTU in the subscriber's VP account or depository until the rights issue has been registered with the Swedish Companies Registration Office, which is expected to take place in week 32 2022.

DELIVERY OF SHARES AND WARRANTS

As soon as the rights issue has been registered at the Swedish Companies Registration Office, estimated around week 32 2022, BTU will be changed to shares and warrants without any special notice from Euroclear.

DILUTION

Through the rights issue of units, the Company's share capital can initially increase by a maximum of SEK 465,353.70 through a rights issue of a maximum of 7,755,895 shares, corresponding to approximately 33.93 percent of the votes and capital in the Company. The dilution is based on the number of issuing shares when preparing this prospectus.

Upon full exercise of warrants of series TO 2 within the framework of the rights issue described in the prospectus, the share capital may increase by a further maximum of SEK 465,353.70, corresponding to an additional approximately 25.33 percent of the votes and capital in the Company.

PUBLICATION OF THE OUTCOME IN THE RIGHTS ISSUE

The announcement of the outcome of the rights issue is made through a press release planned for around the 25th of July 2022, or as soon as possible after the subscription period has ended.

TRADING IN THE SHARE

The shares in the Company are listed on Nasdaq First North Growth Market. The shares are traded under the ticker "PROGEN" and have ISIN code SE0014684569. The new shares will be traded in connection with the conversion from BTU to shares.

APPLICABLE LEGISLATION

The shares are issued under the Swedish Companies Act (2005: 551) and are regulated by Swedish law.

RIGHT TO DIVIDEND

The new shares carry the right to a dividend for the first time on the first record date for dividends that occur after the new shares have been registered with the Swedish Companies Registration Office. The new shares have the same right to dividend as the existing shares.

POSSIBLE RECALCULATION OF SUBSCRIPTION PRICE AND SUBSCRIPTION AUTHORITY

The subscription price and the number of shares in the Company that the warrants entitle to subscribe for may be recalculated in the event of, for example, a bonus issue or new issue. In the event that recalculation becomes relevant, the Company will publish more information about this via its press release on its website (www.prostatypegenomics.com).

GUARANTEE COMMITMENT

During May 2022, the Company entered into a guarantee commitment with board members, existing owners and external investors. The commitment amounts to approximately SEK 14 million. For issued guarantee commitments from guarantors that do not pertain to board members, cash premium compensation of ten percent is paid. For guarantee commitments from board members, cash premium compensation of five percent is paid. Through the guarantee undertaking, the guarantor undertakes to the Company, to the extent that the rights issue is not used to 100 per cent, to subscribe for units in an amount corresponding to the amount of the unused unit rights. The guarantee commitment has not been secured via a prior transaction, bank guarantee or the like, which is why there is a risk that the commitment, in whole or in part, will not be fulfilled.

PRE-SUBSCRIPTION COMMITMENT

The Company has received subscription commitments from a number of existing shareholders and external investors, totalling approximately SEK 8.5 million, corresponding to approximately 38 percent of the offer. No compensation for submitted subscription commitments is paid. Subscription commitments were entered into in May 2022. All investors who have entered into subscription commitments are guaranteed full allotment in accordance with the respective commitment.

OTHER

The Board of Directors of the Company does not have the right to suspend, revoke or temporarily withdraw the offer to subscribe for new shares in the Company in accordance with the terms of this prospectus.

In the event that an excessive amount is paid in by a subscriber for subscribed shares, Nordic Issuing will arrange for the excess amount to be repaid. In such a case, Nordic Issuing will contact the subscriber for information on a bank account to which Nordic Issuing can repay the amount. No interest will be paid for the excess amount. Amounts under 100 SEK are refunded only on request.

Subscription of units is irrevocable, and the subscriber may not cancel or modify a subscription of new units. An incomplete or incorrectly completed subscription form may be submitted without consideration. If the payment for subscribed shares is paid in late, is insufficient or is paid incorrectly, notification of subscription may be submitted without consideration or subscription may be made with a lower amount. Paid cash that has not been used will be refunded.

If several subscription forms of the same category are submitted, only the subscription form that was most recently received by Nordic Issuing will be considered. Late payment of amounts less than SEK 100 will only be refunded on request. Registration of the rights issue with the Swedish Companies Registration Office is expected to take place around week 32 2022.

ISSUING AGENT

Nordic Issuing AB is the issuing agent in connection with the rights issue.